AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by analysts at Citigroup in a report released on Wednesday, Digital Look reports. They currently have a £100 ($130.67) price target on the biopharmaceutical company’s stock, up from their prior price target of GBX 7,000 ($91.47). Citigroup‘s price objective indicates a potential upside of 44.68% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on the stock. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research note on Monday. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, August 27th. Liberum Capital reaffirmed a “hold” rating and set a GBX 6,400 ($83.63) price target on shares of AstraZeneca in a research report on Wednesday, August 28th. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday. Finally, Goldman Sachs Group set a GBX 5,500 ($71.87) price target on AstraZeneca and gave the stock a “sell” rating in a report on Monday, September 2nd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 6,929.41 ($90.55).
Shares of AZN traded up GBX 65 ($0.85) during trading hours on Wednesday, reaching GBX 6,912 ($90.32). 1,040,671 shares of the stock traded hands, compared to its average volume of 2,310,000. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 7,583 ($99.09). The company has a market cap of $90.72 billion and a price-to-earnings ratio of 40.37. The stock has a fifty day simple moving average of GBX 7,113.94 and a 200 day simple moving average of GBX 6,380.91. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What is the market perform rating?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.